Trial Profile
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Blinatumomab (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Rituximab (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Thiotepa (Primary)
- Indications Haematological malignancies; Lymphoid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Non-Hodgkin's lymphoma; Sarcoma
- Focus Therapeutic Use
- 22 Jul 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 22 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jul 2024.
- 25 Jan 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2023.